Mission Statement and Overview

LuxCath is the leader in using fluorescence and optics to directly view lesions during cardiac ablation procedures. The company’s breakthrough technology offers the potential for dramatic evolution in the way ablation procedures are performed by assessing tissue contact and enabling direct lesion progression monitoring.

LuxCath’s patented solution aims to ensure the quality of catheter lesions at the moment they are made. LuxCath enables constant optical tissue contact assessment and provides valuable lesion formation and progression information during each ablation.

One of the biggest challenges with current ablation procedures is the inability to monitor tissue response in real time during the ablation. Detection of gaps between lesions, and the closure of these gaps during radiofrequency ablation, should increase both the safety and efficacy of ablation therapy and enhance the lives of patients while reducing costs.

LuxCath’s new optical tissue characterization and visualization technology offers the opportunity to reduce procedure times and fluoroscopy exposure for patients and practitioners, as well as the number of recurrences due to procedural failures.

LuxCath technology delivers illumination and retrieves tissue fluorescence via optical fiber.

  • Assess electrode-tissue contact before and during ablation
  • Ensure the quality of a lesion as it is made
  • Assess catheter stability
  • Perform contact assessment, lesion progression monitoring and direct lesion visualization
  • Improve patient outcomes while saving money
LuxCath Contact Catheter Instrument

The LuxCath solution may be utilized as a standalone catheter, or as an embedded optical technology that can be integrated into an existing ablation catheter.

Caution: Investigational device. Limited by Federal law to investigational use.


Omar Amirana, MD, CEO
Omar is a Senior Vice President for Allied Minds who currently also serves as CEO of two of the company’s subsidiaries, LuxCath and SciFluor Life Sciences. Previously, Omar was a Partner at Oxford Bioscience Partners, a Boston-based venture capital firm. There, he sourced and led the Series A investment in nFocus Neuromedical, which commercialized a catheter-based aneurysm therapy and was sold to Covidien. Currently on the board of Cardiofocus (AF catheter ablation), Omar has also served on the boards of Flowmedica (renal therapy; sold to AngioDynamics), SmartPill (GI capsule technology; sold to Given Imaging), Coherex (catheter closure of LAA and PFO), Mitralign (percutaneous heart valve repair), and Cambridge Endoscopic Devices (articulating laparoscopic surgical tools). He served as the Vice President of Business Development at St. Jude Medical, and was also co-founder of Cardima (AF ablation; IPO) and Resolution Medical (cardiac mapping), based in Silicon Valley. Omar earned a BS in Mechanical Engineering from Tufts University and an MD from Eastern Virginia Medical School.

Terry Ransbury
Terry has been working in product development since graduating from Duke University with degrees in Biomedical and Electrical Engineering in 1983. He has worked primarily on Class III (life sustaining) medical devices and their instrumentation for companies including Cordis (JNJ), Ventritex (St. Jude Medical), BioSense-Webster (JNJ), Resolution Medical, and InnerPulse. He is the primary inventor on many patents for medical devices that can be found on the web.

KC Armstrong
With nearly 20 years in product development, KC engages in all manner of electrical, software, and mechanical design, system architecture, and technical leadership, and has designed and implemented extensive circuitry and systems for medical, industrial, military, and automotive products. He wields an impressive variety of analytical and design tools, and delights in complex numerical modeling.

Cinnamon Larson, PhD
Cinnamon has a doctorate in mechanical engineering and over 16 years product development and analysis experience. She is a technical specialist in finite element analysis for design creation, optimization, and failure detection. She has extensive experience in project management, requirement development and documentation, regulatory documentation review and development, validation and verification testing development (FEA and testing) and implementation.

James Bowen
James has architected embedded systems in the medical, aerospace, automotive, military, and industrial sectors. His hardware designs are currently depended upon for mission-critical products from Class II surgical devices to power systems for flagship aircraft. His passion is software design: James develops embedded firmware and application software for Class III/II medical devices, as well as real-time multi-core Linux drivers, which push available hardware platforms to their limits.



LuxCath LLC, Demonstrates Promising Results with Optical Tissue Characterization System in Patients during Cardiac Ablation to Cure Arrhythmias; Technology Allows Cardiologists to Continuously "See" Into Heart Tissue with Light

First-In-Man study, a major milestone for the Company, demonstrated highly successful performance of the LuxCath system to optically assess tissue contact before and during ablation.

Read More



LuxCath LLC is a subsidiary of Allied Minds, an innovative U.S. science and technology development and commercialization company. Operating since 2006, Allied Minds forms, funds, manages and builds products and businesses based on innovative technologies developed at leading U.S. universities and federal research institutions. Allied Minds serves as a diversified holding company that supports its businesses and product development with capital, central management and shared services. More information about the Boston-based company can be found at alliedminds.com.

This email address is being protected from spambots. You need JavaScript enabled to view it. to learn more about LuxCath’s revolutionary technology for real time tissue contact assessment and lesion monitoring during cardiac ablation.

100 High St., 28th Floor
Boston, MA 02110
This email address is being protected from spambots. You need JavaScript enabled to view it.